Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
Puma Biotech Inc. is looking forward to going to the top - Industry Global News24
Puma Biotechnology falls more than 20%
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotechnology
SEC charges former Puma biotech exec with $1.1 million in insider trading
Takeda farms out cancer drug alisertib to Puma Biotech -
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotechnology Inc
Puma Biotechnology
Puma Biotechnology, Inc. | LinkedIn
PUMA BIOTECHNOLOGY, INC. : Precio Acción Bourse | PBYI | US74587V1070 | MarketScreener
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
PumaBiotech (@pumabiotech) / Twitter
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Selloff of Puma is an overaction: Analyst
